Guangyan Du - Publications

Affiliations: 
Dana Farber Cancer Institute, Boston, MA, United States 

12 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Powell CE, Du G, Che J, He Z, Donovan KA, Yue H, Wang ES, Nowak RP, Zhang T, Fischer ES, Gray NS. Selective Degradation of GSPT1 by Cereblon Modulators Identified via a Focused Combinatorial Library. Acs Chemical Biology. PMID 32865967 DOI: 10.1021/acschembio.0c00520  0.52
2020 Gurbani D, Du G, Henning NJ, Rao S, Bera AK, Zhang T, Gray NS, Westover KD. Structure and Characterization of a Covalent Inhibitor of Src Kinase. Frontiers in Molecular Biosciences. 7: 81. PMID 32509799 DOI: 10.3389/fmolb.2020.00081  0.52
2020 Xiao H, Jedrychowski MP, Schweppe DK, Huttlin EL, Yu Q, Heppner DE, Li J, Long J, Mills EL, Szpyt J, He Z, Du G, Garrity R, Reddy A, Vaites LP, et al. A Quantitative Tissue-Specific Landscape of Protein Redox Regulation during Aging. Cell. PMID 32109415 DOI: 10.1016/j.cell.2020.02.012  0.52
2020 Du G, Rao S, Gurbani D, Henning NJ, Jiang J, Che J, Yang A, Ficarro SB, Marto JA, Aguirre AJ, Sorger PK, Westover KD, Zhang T, Gray NS. Structure-based design of a potent and selective covalent inhibitor for SRC kinase that targets a p-Loop cysteine. Journal of Medicinal Chemistry. PMID 31935084 DOI: 10.1021/acs.jmedchem.9b01502  0.52
2019 de Wispelaere M, Du G, Donovan KA, Zhang T, Eleuteri NA, Yuan JC, Kalabathula J, Nowak RP, Fischer ES, Gray NS, Yang PL. Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations. Nature Communications. 10: 3468. PMID 31371704 DOI: 10.1038/s41467-019-11429-w  0.52
2019 Scott DA, Hatcher JM, Liu H, Fu M, Du G, Fontán L, Us I, Casalena G, Qiao Q, Wu H, Melnick A, Gray NS. Quinoline and thiazolopyridine allosteric inhibitors of MALT1. Bioorganic & Medicinal Chemistry Letters. PMID 31129051 DOI: 10.1016/j.bmcl.2019.05.040  0.52
2019 Rao S, Gurbani D, Du G, Everley RA, Browne CM, Chaikuad A, Li T, Schröder M, Gondi S, Ficarro SB, Sim T, Kim ND, Berberich MJ, Knapp S, Marto JA, et al. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. Cell Chemical Biology. PMID 30982749 DOI: 10.1016/j.chembiol.2019.02.021  0.52
2019 Hatcher JM, Du G, Fontán L, Us I, Qiao Q, Chennamadhavuni S, Shao J, Wu H, Melnick A, Gray NS, Scott DA. Peptide-based covalent inhibitors of MALT1 paracaspase. Bioorganic & Medicinal Chemistry Letters. PMID 30954428 DOI: 10.1016/j.bmcl.2019.03.046  0.52
2019 Rao S, Du G, Hafner M, Subramanian K, Sorger PK, Gray NS. A multi-targeted probe-based strategy to identify signaling vulnerabilities in cancers. The Journal of Biological Chemistry. PMID 30858179 DOI: 10.1074/jbc.RA118.006805  0.52
2018 Fontán L, Qiao Q, Hatcher JM, Casalena G, Us I, Teater M, Durant M, Du G, Xia M, Bilchuk N, Chennamadhavuni S, Palladino G, Inghirami G, Philippar U, Wu H, et al. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. The Journal of Clinical Investigation. PMID 30024860 DOI: 10.1172/JCI99436  0.52
2016 Tan L, Gurbani D, Weisberg EL, Jones DS, Rao S, Singer WD, Bernard FM, Mowafy S, Jenney A, Du G, Nonami A, Griffin JD, Lauffenburger DA, Westover KD, Sorger PK, et al. Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. Bioorganic & Medicinal Chemistry. PMID 28038940 DOI: 10.1016/j.bmc.2016.11.034  0.52
2016 Tan L, Gurbani D, Weisberg EL, Hunter JC, Li L, Jones DS, Ficarro SB, Mowafy S, Tam CP, Rao S, Du G, Griffin JD, Sorger PK, Marto JA, Westover KD, et al. Structure-guided development of covalent TAK1 inhibitors. Bioorganic & Medicinal Chemistry. PMID 28011204 DOI: 10.1016/j.bmc.2016.11.035  0.52
Show low-probability matches.